{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:31:50Z","timestamp":1775079110001,"version":"3.50.1"},"reference-count":59,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Daratumumab is being increasingly integrated into first-line multiple myeloma (MM) induction regimens, leading to improved response depth and longer progression-free survival. Autologous stem cell transplantation (ASCT) is commonly performed as a consolidation strategy following first-line induction in fit MM patients. We investigated a cohort of 155 MM patients who received ASCT after first-line induction with or without daratumumab (RVd, n = 110; D-RVd, n = 45), analyzing differences in stem cell mobilization, apheresis, and engraftment. In the D-RVd group, fewer patients successfully completed mobilization at the planned apheresis date (44% vs. 71%, p = 0.0029), and more patients required the use of rescue plerixafor (38% vs. 28%, p = 0.3052). The median count of peripheral CD34+ cells at apheresis was lower (41.37 vs. 52.19 \u00d7 106\/L, p = 0.0233), and the total number of collected CD34+ cells was inferior (8.27 vs. 10.22 \u00d7 106\/kg BW, p = 0.0139). The time to recovery of neutrophils and platelets was prolonged (12 vs. 11 days, p = 0.0164; and 16 vs. 14 days, p = 0.0002, respectively), and a higher frequency of erythrocyte transfusions (74% vs. 51%, p = 0.0103) and a higher number of platelet concentrates\/patients were required (4 vs. 2; p = 0.001). The use of daratumumab during MM induction might negatively impact stem cell mobilization and engraftment in the context of ASCT.<\/jats:p>","DOI":"10.3390\/cancers16101854","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T08:33:03Z","timestamp":1715589183000},"page":"1854","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery"],"prefix":"10.3390","volume":"16","author":[{"given":"Julian","family":"Mehl","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1639-3059","authenticated-orcid":false,"given":"Dilara","family":"Akhoundova","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-947X","authenticated-orcid":false,"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Jeker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00eblle","family":"Rhyner Agocs","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, HFR Fribourg-H\u00f4pital Cantonal, 1708 Fribourg, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Ruefer","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cantonal Hospital Lucerne, 6000 Lucerne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Soltermann","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, B\u00fcrgerspital Solothurn, 4500 Solothurn, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Soekler","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Hospital Thun, 3600 Thun, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Winkler","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Biel Hospital Center, 2501 Biel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8138-0505","authenticated-orcid":false,"given":"Michael","family":"Daskalakis","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous Haematopoietic Stem-Cell Transplantation versus Bortezomib\u2013Melphalan\u2013Prednisone, with or without Bortezomib\u2013Lenalidomide\u2013Dexamethasone Consolidation Therapy, and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma (EMN02\/HO95): A Multicentre, Randomised, Open-Label, Phase 3 Study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_5","first-page":"w20031","article-title":"Updated Recommendations for Diagnosis and Treatment of Plasma Cell Myeloma in Switzerland","volume":"149","author":"Samaras","year":"2019","journal-title":"Swiss Med. Wkly."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of Daratumumab to Lenalidomide, Bortezomib, and Dexamethasone for Transplantation-Eligible Patients with Newly Diagnosed Multiple Myeloma (GRIFFIN): Final Analysis of an Open-Label, Randomised, Phase 2 Trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab before and after Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cyto.a.23693","article-title":"High-Parameter Mass Cytometry Evaluation of Relapsed\/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action","volume":"95","author":"Stevenaert","year":"2019","journal-title":"Cytometry A"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors","volume":"186","author":"Tai","year":"2011","journal-title":"J. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab Depletes CD38+ Immune Regulatory Cells, Promotes T-Cell Expansion, and Skews T-Cell Repertoire in Multiple Myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-Mediated Phagocytosis Contributes to the Anti-Tumor Activity of the Therapeutic Antibody Daratumumab in Lymphoma and Multiple Myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fc\u03b3 Receptor\u2013Mediated Cross-Linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"33621","DOI":"10.18632\/oncotarget.26098","article-title":"Trogocytosis Represents a Novel Mechanism of Action of Daratumumab in Multiple Myeloma","volume":"9","author":"Krejcik","year":"2018","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2010.030759","article-title":"Towards Effective Immunotherapy of Myeloma: Enhanced Elimination of Myeloma Cells by Combination of Lenalidomide with the Human CD38 Monoclonal Antibody Daratumumab","volume":"96","author":"Bakker","year":"2011","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1038\/bcj.2011.42","article-title":"The Therapeutic Human CD38 Antibody Daratumumab Improves the Anti-Myeloma Effect of Newly Emerging Multi-Drug Therapies","volume":"1","author":"Bakker","year":"2011","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of Lenalidomide Therapy on Stem Cell Mobilization and Engraftment Post-Peripheral Blood Stem Cell Transplantation in Patients with Newly Diagnosed Myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-020-04376-w","article-title":"Comparison of the Efficiency, Safety, and Survival Outcomes in Two Stem Cell Mobilization Regimens with Cyclophosphamide plus G-CSF or G-CSF Alone in Multiple Myeloma: A Meta-Analysis","volume":"100","author":"Wang","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/s41409-020-0875-8","article-title":"A Randomized Evaluation of Vinorelbine versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients","volume":"55","author":"Jeker","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"B\u00fchler, S., Akhoundova, D., Jeker, B., Legros, M., Seipel, K., Daskalakis, M., Bacher, U., and Pabst, T. (2023). Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma. Cancers, 15.","DOI":"10.3390\/cancers15020430"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3109\/10428194.2014.927454","article-title":"Role of Plerixafor in Autologous Stem Cell Mobilization with Vinorelbine Chemotherapy and Granulocyte-Colony Stimulating Factor in Patients with Myeloma: A Phase II Study (PAV-Trial)","volume":"56","author":"Schmid","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/bmt.2017.234","article-title":"NSAID Treatment with Meloxicam Enhances Peripheral Stem Cell Mobilization in Myeloma","volume":"53","author":"Jeker","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2141.2003.04107.x","article-title":"Mobilization of CD34+ Cells in Elderly Patients (\u226570 Years) with Multiple Myeloma: Influence of Age, Prior Therapy, Platelet Count and Mobilization Regimen","volume":"120","author":"Morris","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1080\/10428194.2016.1233542","article-title":"Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Evaluation of Its Safety and Efficacy","volume":"58","author":"Stettler","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2895.x","article-title":"Effect of CD34+ Cell Dose on Hematopoietic Reconstitution and Outcome in 508 Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation","volume":"78","author":"Klaus","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1182\/blood.V86.10.3961.bloodjournal86103961","article-title":"An Analysis of Engraftment Kinetics as a Function of the CD34 Content of Peripheral Blood Progenitor Cell Collections in 692 Patients After the Administration of Myeloablative Chemotherapy","volume":"86","author":"Weaver","year":"1995","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/bbmt.1998.v4.pm9763111","article-title":"Effect of CD34+ Peripheral Blood Progenitor Cell Dose on Hematopoietic Recovery","volume":"4","author":"Shpall","year":"1998","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_30","unstructured":"Zappaterra, A., Civettini, I., Cafro, A.M., Pezzetti, L., Pierini, S., Anghilieri, M., Bellio, L., Bertazzoni, P., Grillo, G., and Minga, P. (2024). Anti-CD38 Monoclonal Antibody Impairs CD34+ Mobilization and Affects Clonogenic Potential in Multiple Myeloma Patients: CD38 Antibody Impacts on HSC Mobilization and Clonogenicity. Blood Transfus."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2023-185907","article-title":"Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analysis","volume":"142","author":"Cavallaro","year":"2023","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1182\/blood-2022-169367","article-title":"Despite Use of Upfront Plerixafor and G-CSF, Daratumumab Exposure Reduces Stem Cell Mobilization in Patients with Multiple Myeloma","volume":"140","author":"Edmisson","year":"2022","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1080\/10428194.2023.2253479","article-title":"Impact of Daratumumab on Stem Cell Mobilization and Collection, Engraftment and Early Post-Transplant Complications among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation","volume":"64","author":"Terpos","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3324\/haematol.2022.281610","article-title":"Impact of Daratumumab-Based Induction on Stem Cell Collection Parameters in Swedish Myeloma Patients","volume":"108","author":"Lemonakis","year":"2022","journal-title":"Haematologica"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.1182\/blood-2023-180082","article-title":"Impact of Daratumumab on Hematopoietic Stem Cell Mobilization with G-CSF and on-Demand Plerixafor in Newly-Diagnosed Multiple Myeloma Patients","volume":"142","author":"Mina","year":"2023","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"10441","DOI":"10.1182\/blood-2022-171098","article-title":"Effect of Daratumumab on Stem Cell Mobilization and Engraftment Kinetics Post Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma","volume":"140","author":"Oza","year":"2022","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"340.e1","DOI":"10.1016\/j.jtct.2023.02.013","article-title":"Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience","volume":"29","author":"Thurlapati","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_38","first-page":"E8","article-title":"Delayed Neutrophil Engraftment in Patients Receiving Daratumumab as Part of Their First Induction Regimen for Multiple Myeloma","volume":"95","author":"Sidiqi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3324\/haematol.2020.261842","article-title":"Stem Cell Yield and Transplantation in Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients Receiving Daratumumab + Bortezomib\/Thalidomide\/Dexamethasone in the Phase 3 CASSIOPEIA Study","volume":"106","author":"Hulin","year":"2021","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-140811","article-title":"Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use","volume":"136","author":"Luan","year":"2020","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000529691","article-title":"Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma","volume":"50","author":"Sauer","year":"2023","journal-title":"Transfus. Med. Hemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.bmt.1703787","article-title":"Mobilization of Peripheral Blood Progenitor Cells with Vinorelbine and Granulocyte Colony-Stimulating Factor in Multiple Myeloma Patients Is Reliable and Cost Effective","volume":"31","author":"Bargetzi","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bbmt.2014.09.020","article-title":"Efficacy of Vinorelbine Plus Granulocyte Colony\u2013Stimulation Factor for CD34+ Hematopoietic Progenitor Cell Mobilization in Patients with Multiple Myeloma","volume":"21","author":"Samaras","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.3109\/10428194.2015.1079315","article-title":"Stem Cell Mobilization Chemotherapy with Gemcitabine Is Effective and Safe in Myeloma Patients with Bortezomib-Induced Neurotoxicity","volume":"57","author":"Mueller","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/scd.1.1996.5.213","article-title":"The ISHAGE Guidelines for CD34+ Cell Determination by Flow Cytometry","volume":"5","author":"Sutherland","year":"1996","journal-title":"J. Hematother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S513","DOI":"10.1016\/S2152-2650(23)01480-5","article-title":"MM-644 Daratumumab Does Not Significantly Affect the Yield of Stem Cell Mobilization or Risk of Post-Transplant Infections in Patients With Multiple Myeloma","volume":"23","author":"Hodroj","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-142115","article-title":"Impact of Daratumumab on Stem Cell Collection, Graft Composition and Engraftment Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant","volume":"136","author":"Manjappa","year":"2020","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Gillich, C., Akhoundova, D., Hayoz, M., Aebi, Y., Largiad\u00e8r, C.R., Seipel, K., Daskalakis, M., Bacher, U., and Pabst, T. (2023). Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma. Cancers, 15.","DOI":"10.3390\/cancers15102699"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/hon.2673","article-title":"Autologous Stem Cell Transfusions on Multiple Days in Patients with Multiple Myeloma\u2014Does It Matter?","volume":"37","author":"Moser","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-018-0119-4","article-title":"Daratumumab Binds to Mobilized CD34+ Cells of Myeloma Patients in Vitro without Cytotoxicity or Impaired Progenitor Cell Growth","volume":"7","author":"Ma","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 Expression and Complement Inhibitors Affect Response and Resistance to Daratumumab Therapy in Myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8588","DOI":"10.1200\/jco.2015.33.15_suppl.8588","article-title":"Effect of IMiD Compounds on CD38 Expression on Multiple Myeloma Cells: MOR202, a Human CD38 Antibody in Combination with Pomalidomide","volume":"33","author":"Boxhammer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2141.1998.01015.x","article-title":"All-Trans-Retinoic Acid up-Regulates CD38 but Not c-Kit Antigens on Human Marrow CD34+ Cells without Recruitment into Cell Cycle","volume":"103","author":"Herault","year":"1998","journal-title":"Br. J. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e1486948","DOI":"10.1080\/2162402X.2018.1486948","article-title":"Daratumumab Induces CD38 Internalization and Impairs Myeloma Cell Adhesion","volume":"7","author":"Ghose","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_58","first-page":"1439","article-title":"Insight into the Mechanism of CD34+ Cell Mobilisation Impairment in Multiple Myeloma Patients Treated with Anti-CD38 Therapy","volume":"4","author":"Venglar","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_59","first-page":"10","article-title":"Cell Adhesion Molecule Expression on CD34+ Cells in Grafts and Time to Myeloid and Platelet Recovery after Autologous Stem Cell Transplantation","volume":"26","author":"Watanabe","year":"1998","journal-title":"Exp. Hematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/10\/1854\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:41:15Z","timestamp":1760107275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/10\/1854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":59,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["cancers16101854"],"URL":"https:\/\/doi.org\/10.3390\/cancers16101854","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]}}}